Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iafrate

Showing results (511-520 of 580) with videos related to

Pageof 58
Sort By:
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast CancerNeelima Vidula, Taronish Dubash, Michael S Lawrence, et al.
British Journal of Cancer|June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerA F Hezel, M S Noel, J N Allen, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2Niamh Coleman, Zihan Wei, A John Iafrate, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
The Journal of Infectious Diseases|December 10, 2021
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 VaccinesVivek Naranbhai, Wilfredo F Garcia-Beltran, Christina C Chang, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccinesVivek Naranbhai, Wilfredo F Garcia-Beltran, Christina C Chang, et al.
Pageof 58

Showing results (511-520 of 580) with videos related to

Sort By:
Pageof 58
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2020
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast CancerNeelima Vidula, Taronish Dubash, Michael S Lawrence, et al.
British Journal of Cancer|June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerA F Hezel, M S Noel, J N Allen, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2Niamh Coleman, Zihan Wei, A John Iafrate, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
The Journal of Infectious Diseases|December 10, 2021
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 VaccinesVivek Naranbhai, Wilfredo F Garcia-Beltran, Christina C Chang, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccinesVivek Naranbhai, Wilfredo F Garcia-Beltran, Christina C Chang, et al.
Pageof 58